Market Monitor - Chemicals performance - Switzerland

Market Monitor

  • Schweiz
  • Kemi/Medicinalvarer

01 Jun 2015

Chemicals/pharmaceuticals has been a well performing sector in Switzerland; demand and profit margins are expected to remain stable in 2015.

Market performance at a glance 

Switzerland

  • The performance of the Swiss chemicals/pharmaceuticals industry has been strong for years, with most businesses showing good financial health. Businesses´ gearing is generally low, while banks are very willing to provide loans.
  • Many Swiss companies in this sector benefit from a geographically well diversified customer portfolio, which ensures a good risk distribution of their trade receivables.
  • As many Swiss chemicals/pharmaceuticals businesses have diversified their production sites outside Switzerland, they are among the Swiss export-driven sectors that are least affected by the appreciation of the Swiss franc.
  • Demand and profit margins in this industry are expected to remain stable in 2015.
  • The average payment duration in the Swiss chemicals/pharmaceuticals industry is 45 to 60 days. The number of protracted payments, non-payments and insolvency cases is traditionally low, and it is expected that there will be no change in the coming months.
  • Due to the general positive indicators, our underwriting stance continues to be relaxed for all segments of this industry.

Relaterede dokumenter

Ansvarsfraskrivelse

Oplysningerne heri er udelukkende informative og må ikke bruges til andre formål. Se venligst den aktuelle police eller den relevante produkt- eller serviceaftale for de gældende betingelser. Intet heri medfører nogen rettighed, forpligtelse eller ansvar på vegne af Atradius, herunder enhver forpligtelse til at foretage due diligence af købere eller på dine vegne. Hvis Atradius foretager en due diligence vedr. en køber, er det for egne forsikringstekniske formål og ikke til fordel for den forsikrede eller nogen anden person. Ydermere må Atradius eller dets tilknyttede virksomheder eller datterselskaber ikke på noget tidspunkt være ansvarlig for direkte, indirekte, konkret dokumenterede tab eller følgetab, der måtte opstå som følge af brugen af udtalelserne i denne information